SeaCrest Wealth Management’s Harvard Bioscience HBIO Stock Holding History

SeaCrest Wealth Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-80	Closed	-$3K	–	1069
2019 Q1	$3K	Hold	80	–	–	﹤0.01%	1843
2018 Q4	$3K	Sell	80 -80	-50%	-$3.15K	﹤0.01%	1822
2018 Q3	$8K	Buy	160 +80	+100%	+$4.49K	﹤0.01%	1721
2018 Q2	$4K	Hold	80	–	–	﹤0.01%	1872
2018 Q1	$4K	Hold	80	–	–	﹤0.01%	1842
2017 Q4	$3K	Buy	+80	New	+$2.7K	﹤0.01%	1926

Other funds holding HBIO

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ECM

Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DGHMC

Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

SeaCrest Wealth Management's HBIO Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Harvard Bioscience (HBIO) in Q2 2019, closing a stake of 80 shares — an estimated $3K sold.

SeaCrest Wealth Management first reported a position in HBIO in Q4 2017 and held it in 6 quarters. The position peaked at $8K in Q3 2018. 78 funds tracked by Wall St. Rank hold HBIO as of Q2 2019.

SeaCrest Wealth Management reported no remaining Harvard Bioscience position as of Q2 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 80 Harvard Bioscience shares in Q2 2019, an estimated $3K.
SeaCrest Wealth Management first reported a position in Harvard Bioscience in Q4 2017 and held it in 6 quarters.
SeaCrest Wealth Management's Harvard Bioscience position peaked at $8K in Q3 2018.
78 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.